Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 23539269)

1.

Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN.

Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, Bajrami I, McGonnell IM, Lord CJ, Reis RM, Hargrave D, Ashworth A, Workman P, Jones C.

Cancer Discov. 2013 May;3(5):512-9.

2.

G34, another connection between MYCN and a pediatric tumor.

Huang M, Weiss WA.

Cancer Discov. 2013 May;3(5):484-6. doi: 10.1158/2159-8290.CD-13-0126.

3.

Glioblastoma: histone mutations take the MYCN.

McCarthy N.

Nat Rev Cancer. 2013 Jun;13(6):382-3. doi: 10.1038/nrc3527. Epub 2013 Apr 25. No abstract available.

PMID:
23615692
4.

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tönjes M, Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, Lindroth A, Jäger N, Rausch T, Ryzhova M, Korbel JO, Hielscher T, Hauser P, Garami M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheurlen W, Pekrun A, Frühwald MC, Roggendorf W, Kramm C, Dürken M, Atkinson J, Lepage P, Montpetit A, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel P, Kulozik AE, Zapatka M, Guha A, Malkin D, Felsberg J, Reifenberger G, von Deimling A, Ichimura K, Collins VP, Witt H, Milde T, Witt O, Zhang C, Castelo-Branco P, Lichter P, Faury D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N.

Nature. 2012 Jan 29;482(7384):226-31. doi: 10.1038/nature10833. Erratum in: Nature. 2012 Apr 5;484(7392):130.

PMID:
22286061
5.

Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.

Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, Santi M, Thompson CB, Judkins AR.

Brain Pathol. 2013 Sep;23(5):558-64. doi: 10.1111/bpa.12042. Epub 2013 Mar 6.

6.

Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, Aldape K, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM.

Cancer Cell. 2012 Oct 16;22(4):425-37. doi: 10.1016/j.ccr.2012.08.024.

7.

A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?

Chan KM, Han J, Fang D, Gan H, Zhang Z.

Cell Cycle. 2013 Aug 15;12(16):2546-52. doi: 10.4161/cc.25625. Epub 2013 Jul 10.

8.

Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.

Jha P, Pia Patric IR, Shukla S, Pathak P, Pal J, Sharma V, Thinagararanjan S, Santosh V, Suri V, Sharma MC, Arivazhagan A, Suri A, Gupta D, Somasundaram K, Sarkar C.

Neuro Oncol. 2014 Dec;16(12):1607-17. doi: 10.1093/neuonc/nou113. Epub 2014 Jul 4.

PMID:
24997139
9.

Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas.

Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DT, Kool M, Zapatka M, Northcott PA, Sturm D, Wang W, Radlwimmer B, Højfeldt JW, Truffaux N, Castel D, Schubert S, Ryzhova M, Seker-Cin H, Gronych J, Johann PD, Stark S, Meyer J, Milde T, Schuhmann M, Ebinger M, Monoranu CM, Ponnuswami A, Chen S, Jones C, Witt O, Collins VP, von Deimling A, Jabado N, Puget S, Grill J, Helin K, Korshunov A, Lichter P, Monje M, Plass C, Cho YJ, Pfister SM.

Cancer Cell. 2013 Nov 11;24(5):660-72. doi: 10.1016/j.ccr.2013.10.006. Epub 2013 Oct 31.

10.

A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas.

Venneti S, Santi M, Felicella MM, Yarilin D, Phillips JJ, Sullivan LM, Martinez D, Perry A, Lewis PW, Thompson CB, Judkins AR.

Acta Neuropathol. 2014 Nov;128(5):743-53. doi: 10.1007/s00401-014-1338-3. Epub 2014 Sep 9.

11.

Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail.

Fontebasso AM, Liu XY, Sturm D, Jabado N.

Brain Pathol. 2013 Mar;23(2):210-6. doi: 10.1111/bpa.12023. Review.

PMID:
23432647
12.

Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma.

Murphy DM, Buckley PG, Das S, Watters KM, Bryan K, Stallings RL.

PLoS One. 2011;6(6):e21436. doi: 10.1371/journal.pone.0021436. Epub 2011 Jun 22.

13.

Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM.

Pathak P, Jha P, Purkait S, Sharma V, Suri V, Sharma MC, Faruq M, Suri A, Sarkar C.

J Neurooncol. 2015 Feb;121(3):489-97. doi: 10.1007/s11060-014-1675-z. Epub 2014 Dec 6.

PMID:
25479829
14.

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.

Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z.

Genes Dev. 2013 May 1;27(9):985-90. doi: 10.1101/gad.217778.113. Epub 2013 Apr 19.

15.

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, Molenaar JJ, van Nes J, Versteeg R.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.

16.

Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation.

Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, Prenter S, Bray I, Watters KM, Higgins D, Stallings RL.

PLoS One. 2009 Dec 4;4(12):e8154. doi: 10.1371/journal.pone.0008154.

17.

Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.

Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Thériault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW, Pang R, Massey C, Godbout R, Jiang Z, Zacksenhaus E, Paton K, Moll AC, Houdayer C, Raizis A, Halliday W, Lam WL, Boutros PC, Lohmann D, Dorsman JC, Gallie BL.

Lancet Oncol. 2013 Apr;14(4):327-34. doi: 10.1016/S1470-2045(13)70045-7. Epub 2013 Mar 13.

18.

BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.

Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, Barbash O, Le B, Craggs PD, McCabe MT, Kennedy-Wilson KM, Sanchez LV, Gosmini RL, Parr N, McHugh CF, Dhanak D, Prinjha RK, Auger KR, Tummino PJ.

PLoS One. 2013 Aug 23;8(8):e72967. doi: 10.1371/journal.pone.0072967. eCollection 2013.

19.

Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.

Schramm A, Köster J, Marschall T, Martin M, Schwermer M, Fielitz K, Büchel G, Barann M, Esser D, Rosenstiel P, Rahmann S, Eggert A, Schulte JH.

Int J Cancer. 2013 Feb 1;132(3):E106-15. doi: 10.1002/ijc.27787. Epub 2012 Sep 26.

PMID:
22907398
20.

Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.

Tabone T, Abuhusain HJ, Nowak AK; Australian Genomics and Clinical Outcome of Glioma (AGOG) Network, Erber WN, McDonald KL.

J Clin Pathol. 2014 Jul;67(7):550-5. doi: 10.1136/jclinpath-2014-202173. Epub 2014 Apr 2.

PMID:
24695838
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk